Last reviewed · How we verify

Drug-eluting Stent Mometasone

Children's Hospital Medical Center, Cincinnati · FDA-approved active Small molecule

A drug-eluting stent that releases mometasone (a corticosteroid) locally to reduce inflammation and restenosis at the site of coronary or vascular intervention.

A drug-eluting stent that releases mometasone (a corticosteroid) locally to reduce inflammation and restenosis at the site of coronary or vascular intervention. Used for Coronary artery disease requiring percutaneous coronary intervention, Prevention of in-stent restenosis.

At a glance

Generic nameDrug-eluting Stent Mometasone
Also known asMometasone
SponsorChildren's Hospital Medical Center, Cincinnati
Drug classDrug-eluting stent (corticosteroid-eluting)
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Mometasone is a potent glucocorticoid that suppresses the inflammatory response triggered by stent placement, reducing neointimal hyperplasia and the risk of in-stent restenosis. By eluting the drug directly at the intervention site over time, local anti-inflammatory effects are achieved while minimizing systemic exposure. This approach aims to improve long-term patency and reduce the need for repeat revascularization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: